Building a multibillion-dollar synthetic biology industry
SynbiTECH 2019: Evolve, Enable, Expand: Engineering the future with Synthetic Biology
Reasons to attend
SynbiTECH is an international conference taking place this June in London for experts engaged in synthetic biology research, commercialisation, investment and policymaking. SynbiTECH 2019 will focus on the key opportunities and challenges for building a multibillion-dollar synthetic biology industry that will contribute to the fast-growing bio-economy.
Don't miss the insightful 'Synbio unplugged' sessions, panel discussions and keynote presentations. With our fast-growing global population, our rapid use of the world's finite resources and the damaging impacts of climate change on the environment, there is an URGENT need to radically re-think how to sustain future human activity. Bring your expertise and contribute to the debate.
Join world-leading experts to discover the many opportunities created by the synergy between biology, engineering and technology. Help to unleash the power of synthetic biology and discover how your business can succeed in the future bio-economy.
An opportunity to showcase knowledge and innovation across synthetic biology. Demonstrate to our expert audience how your business is delivering a difference, the value of your technology and discover potential partners and customers.
Share this conference and the benefits of attending with your colleagues - download our '6 Key Reasons to Attend' flyer now
A diverse panel of speakers has been carefully selected with the core theme of this year's conference in mind. Synthetic biology has grown dramatically in the last five years but we've seen only a fraction of its potential to make a positive contribution to the challenges the world faces and to grow some exciting new businesses. SynbiTECH is going to bring together the outcome of decades of research and discovery and the cross-disciplinary sharing of ideas from brilliant minds in science, engineering and technology. Speakers from across the world will share their opinion, insights and expertise at this not to be missed event as we accelerate toward realising synthetic biology's true potential.
Amadeus Capital Partners
Dr Hermann Hauser
Co-founder & Venture Partner, Amadeus Capital Partners
In 2015 Hermann was awarded a KBE for services to Engineering and Industry.
Serial Entrepreneur and Co-founder of Amadeus Capital Partners, Dr Hermann Hauser KBE has wide experience in developing and financing companies in the information technology sector. He co-founded a number of high-tech companies including Acorn Computers which spun out ARM, E-trade UK, Virata and Cambridge Network. Subsequently, Hermann became vice president of research at Olivetti. During his tenure at Olivetti, he established a global network of research laboratories. Since leaving Olivetti, Hermann has founded over 20 technology companies. In 1997, he co-founded Amadeus Capital Partners. At Amadeus he invested in CSR, Solexa, Icera, Xmos and Cambridge Broadband.
Hermann is a Fellow of the Royal Society, the Institute of Physics, the Royal Society of Chemistry and of the Royal Academy of Engineering, as well as an Honorary Fellow of King's College, Cambridge. In 2001 he was awarded an Honorary CBE for ‘innovative service to the UK enterprise sector’. In 2004 he was made a member of the Government’s Council for Science and Technology and in 2013 he was made a Distinguished Fellow of BCS, the Chartered Institute for IT.
Hermann has honorary doctorates from the Universities of Loughborough, Bath, Anglia Ruskin, Strathclyde, Glasgow and York.
Sustainability and Innovation Director, Stella McCartney
Claire Bergkamp joined Stella McCartney in 2012 and is the Worldwide Director of Sustainability and Innovation. During her tenure, Claire has helped establish the brand’s leadership and reputation in sustainability. Developing its robust environmental and social improvement strategy and worked across the brand and its supply chain internationally to implement it. Claire has focused particularly on sustainable raw material development and procurement, as well as driving alternative materials and innovation. As such, she works closely with innovators, start-ups and universities to find new sustainable business models and solutions. A key element of her sustainability approach includes supplier engagement and the ongoing improvement in social welfare across the supply chain. Within this context, she also oversees Stella McCartney's ethical trade and community outreach programmes.
Lord David Willetts
Executive Chair, Resolution Foundation
The Rt Hon. Lord David Willetts FRS is the Executive Chair of the Resolution Foundation. He served as the Member of Parliament for Havant (1992-2015), as Minister for Universities and Science (2010-2014) and previously worked at HM Treasury and the No. 10 Policy Unit.
Lord Willetts is a visiting Professor at King’s College London, a Board member of UK Research and Innovation (UKRI), a Board member of Surrey Satellites and of the Biotech Growth Trust. He is the Chair of the Sanger Institute and the Chair of Foundation for Science and Technology. He is an Honorary Fellow of Nuffield College, an Honorary fellow of the Royal Society and the Chancellor of the University of Leicester.
Lord Willetts has written widely on economic and social policy. His book ‘The Pinch’ about fairness between the generations was published in 2010. His latest book “A University Education” is published by Oxford University Press.
Dr Jason Kelly
Co-Founder and CEO, Ginkgo BioWorks
Jason Kelly is the co-founder and CEO of Ginkgo Bioworks. Ginkgo is a synthetic biology company that genetically engineers "made-to-order" cells for customers in the chemical, pharmaceutical, food, and energy industries.
The company engineers these cells in their 100,000 sqft automated genetic engineering foundry and has partnerships with companies including ADM, Cargill, and Ajinomoto as well as top 5 beverage, petrochemical, and electronics companies. Ginkgo recently announced a $100M joint venture with Bayer to develop microbes to make food crops self-fertilizing and in 2017 Ginkgo was selected #7 on CNBC's Disruptor 50 List of fast-growing companies.
Jason has previously spoken at the World Economic Forum in Davos, the Allen & Co Sun Valley conference, and the US Library of Congress. Prior to Ginkgo, Jason received B.S. degrees in Chemical Engineering and Biology and a PhD in Biological Engineering all from MIT.
Oxford Nanopore Technologies
Professor Hagan Bayley
Co-Founder, Oxford Nanopore Technologies
Hagan Bayley is Professor of Chemical Biology at the University of Oxford. Major interests of his laboratory are the development of engineered pores for stochastic sensing, the study of covalent chemistry at the single molecule level, ultra-rapid DNA sequencing and the fabrication of synthetic tissues.
He received his B.A. in chemistry from Oxford in 1974, while at Balliol College, and his Ph.D. in chemistry from Harvard University in 1979 in the laboratory of Jeremy Knowles. After postdoctoral work with Gobind Khorana at the Massachusetts Institute of Technology, he was on the faculty at Columbia University and the University of Oxford. From 1988 to 1996, he was at the Worcester Foundation for Experimental Biology in Shrewsbury, Massachusetts, and from 1997 to 2003 at Texas A&M University in College Station.
In 2005, Professor Bayley founded Oxford Nanopore to exploit the potential of stochastic sensing technology. The company has developed the MinION portable DNA sequencer. In 2014, he founded OxSyBio to build synthetic tissues for regenerative medicine. He has been a recipient of the Royal Society’s Wolfson Research Merit Award and was the 2009 Chemistry World Entrepreneur of the Year. In 2011, Professor Bayley was elected a Fellow of the Royal Society. In 2012, he was awarded the Royal Society of Chemistry's Interdisciplinary Prize and in 2017, the Menelaus Medal of the Learned Society of Wales. In, 2018 Professor Bayley held the Kavli Chair at TU Delft.
Two days of carefully curated topics, delivered in a simple format, to ensure delegates are able to attend sessions most relevant to them. Networking is all-inclusive and we invite all attendees to enjoy the champagne evenings at the end of both days.
Presidents of the conference
Professor Paul Freemont
Paul has been working at the forefront of international synthetic biology developments since 2002 and has played a key role in developing from the outset the UK strategy for synthetic biology research, innovation and training.
A leading figure in synthetic biology, he has played a key part in the development of synthetic biology in the UK and was a co-author of the British Government’s UK Synthetic Biology Roadmap. Paul has been a passionate advocate for synthetic biology research and translation both in Europe and internationally and has participated as a technical expert in the United Nations Convention for Biological Diversity and Biological Weapons Convention. He is also a working group member of the US NIST synthetic biology standards consortium.
Paul’s research interests span from understanding the molecular mechanisms of human diseases and infection to the development of synthetic biology platform technologies and biosensors and he is the author of over 170 peer-reviewed scientific publications. He gives many lectures both at international scientific meetings and also public lecture - the most recent being the Ellison-Cliffe medal lecture at the Royal Society of Medicine.
Paul co-founded and co-directs the UK’s first academic research centre for synthetic biology at Imperial College London (CSynBI) and the first R&D centre for synthetic biology SynbiCITE.
Paul is also very active in public engagement including numerous public debates - the most recent at the Royal Institution and public displays including at the Science Museum and the first ‘pop-up’ lab at the Victoria and Albert Museum. He is also an advocate for training young people and talks regularly at schools and has successfully co-supervised Imperial undergraduate iGEM teams since 2006.
Professor Richard Kitney
Professor Kitney has been working at the forefront of synthetic biology and has been pivotal in shaping its development in the UK and internationally since 2003.
He has championed synthetic biology to governments, industry, learned societies and the public. Kitney is globally recognised as pioneering in the field. Dick has been a leader of UK R&D and the translation of synthetic biology for more than a decade, promoting global synthetic biology developments.
As Chair of The Royal Academy of Engineering’s Inquiry into Synthetic Biology and a member of the UK’s Ministerial Synthetic Biology Leadership Council, Dick has driven the UK’s approach to the field and the technology, its development and its translation into industrially useful products, tools, processes and services - alongside educating future synthetic biologists. In addition to The Royal Academy of Engineering Inquiry Report (Synthetic biology – Scope, Applications and Implications, 2009), he is one of the authors of the two, subsequent, UK roadmaps for synthetic biology (A Synthetic Biology Roadmap for the UK, 2012; and Bio Design for the Bio Economy, 2016).
Dick Co-Directs the UK’s first R&D centre for Synthetic Biology and Innovation (CSynBI) and the UK’s National Industrial Translation Centre for Synthetic Biology (SynbiCITE).
He gives many keynote presentations at public lectures and international conferences – recently the IET Kelvin Lecture and the City and Guilds Fellowship Lecture.
The prestigious Queen Elizabeth II (QEII) Centre is in the heart of Westminster, central London. Opened in 1986 by HM The Queen, the Centre is the ideal location to welcome business leaders, investors, policy makers and academics from around the world.